| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| N A Votolato, S Stern, R M Caput. Serotonergic antidepressants and urinary incontinence. International urogynecology journal and pelvic floor dysfunction. vol 11. issue 6. 2001-03-01. PMID:11147747. |
in the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine. |
2001-03-01 |
2023-08-12 |
Not clear |
| R Zanardi, F Artigas, R Moresco, C Colombo, C Messa, C Gobbo, E Smeraldi, F Fazi. Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan study. Journal of clinical psychopharmacology. vol 21. issue 1. 2001-03-01. PMID:11199948. |
using positron emission tomography (pet) scanning, the authors examined the cortical 5-hydroxytryptamine-2a (5-ht2a) receptor binding of [18f]fluoro-ethyl-spiperone after a 4-week treatment with the selective serotonin reuptake inhibitor paroxetine. |
2001-03-01 |
2023-08-12 |
human |
| F R Schneie. Treatment of social phobia with antidepressants. The Journal of clinical psychiatry. vol 62 Suppl 1. 2001-03-01. PMID:11206033. |
selective serotonin reuptake inhibitors (ssris), of which paroxetine has been the best studied in social phobia to date, have recently emerged as a first-line treatment for the generalized subtype of social phobia. |
2001-03-01 |
2023-08-12 |
Not clear |
| J H Meyer, S Kapur, B Eisfeld, G M Brown, S Houle, J DaSilva, A A Wilson, S Rafi-Tari, H S Mayberg, S H Kenned. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. The American journal of psychiatry. vol 158. issue 1. 2001-02-22. PMID:11136637. |
the effect of paroxetine on 5-ht(2a) receptors in depression: an [(18)f]setoperone pet imaging study. |
2001-02-22 |
2023-08-12 |
Not clear |
| J H Meyer, S Kapur, B Eisfeld, G M Brown, S Houle, J DaSilva, A A Wilson, S Rafi-Tari, H S Mayberg, S H Kenned. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. The American journal of psychiatry. vol 158. issue 1. 2001-02-22. PMID:11136637. |
the objective of this study was to evaluate the effect of 6 weeks of paroxetine treatment on 5-ht(2a) receptors in depressed patients. |
2001-02-22 |
2023-08-12 |
Not clear |
| J M Gerdes, S C DeFina, P A Wilson, S E Taylo. Serotonin transporter inhibitors: synthesis and binding potency of 2'-methyl- and 3'-methyl-6-nitroquipazine. Bioorganic & medicinal chemistry letters. vol 10. issue 23. 2001-02-15. PMID:11128642. |
racemic 2'-methyl- and 3'-methyl-6-nitroquipazine ligands were selected as targets, synthesized and evaluated at the serotonin transporter employing an in vitro competitive inhibition assay with [3h]paroxetine and rat cortical membrane. |
2001-02-15 |
2023-08-12 |
rat |
| H Bird, M Broggin. Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double blind, parallel group study. The Journal of rheumatology. vol 27. issue 12. 2001-02-08. PMID:11128665. |
to compare the efficacy and tolerability of paroxetine (a selective serotonin reuptake inhibitor) with that of amitriptyline (a tricyclic antidepressant) in the treatment of depression in 191 patients with rheumatoid arthritis (ra). |
2001-02-08 |
2023-08-12 |
Not clear |
| b' M Maes, R Verkerk, L Delmeire, A Van Gastel, F van Hunsel, S Scharp\\xc3\\xa. Serotonergic markers and lowered plasma branched-chain-amino acid concentrations in fibromyalgia. Psychiatry research. vol 97. issue 1. 2001-01-26. PMID:11104853.' |
[3h]paroxetine binding characteristics and the availability of plasma tryptophan, the precursor of serotonin (5-ht), and the plasma concentrations of the branched chain amino acids (bcaas), valine, leucine and isoleucine, in fibromyalgia. |
2001-01-26 |
2023-08-12 |
human |
| M S Duxon, K R Starr, N Upto. Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT(1A) receptor antagonist WAY100635. British journal of pharmacology. vol 130. issue 7. 2001-01-25. PMID:10928979. |
to assess whether concurrent 5-ht(1a) receptor blockade reduces the time to onset of anxiolysis seen with paroxetine alone (21 days), rats were implanted with osmotic minipumps to continuously infuse the 5-ht(1a) receptor antagonist way100635 (1 mg kg(-1) day(-1), s.c., 7 days) alone or in combination with paroxetine (3 mg kg(-1), p.o., daily, 7 days), prior to anxiety testing. |
2001-01-25 |
2023-08-12 |
rat |
| M S Duxon, K R Starr, N Upto. Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT(1A) receptor antagonist WAY100635. British journal of pharmacology. vol 130. issue 7. 2001-01-25. PMID:10928979. |
this data demonstrates that coadministration of a 5-ht(1a) receptor antagonist with paroxetine markedly reduces the latency to anxiolysis, in the rat. |
2001-01-25 |
2023-08-12 |
rat |
| D S Baldwi. Clinical experience with paroxetine in social anxiety disorder. International clinical psychopharmacology. vol 15 Suppl 1. 2001-01-11. PMID:10994679. |
paroxetine is a selective serotonin reuptake inhibitor (ssri) with proven efficacy in the treatment of depression, panic disorder and obsessive-compulsive disorder. |
2001-01-11 |
2023-08-12 |
Not clear |
| J Vetulani, I Nalep. Antidepressants: past, present and future. European journal of pharmacology. vol 405. issue 1-3. 2001-01-08. PMID:11033340. |
the novel antidepressants are either selective and reversible monoamine oxidase inhibitors, (e.g., moclobemide), or selective serotonin reuptake inhibitors (e.g., citalopram or paroxetine), or serotonin and noradrenaline reuptake inhibitors (e.g. |
2001-01-08 |
2023-08-12 |
Not clear |
| M Hascoët, M Bourin, B A Nic Dhonnchadh. The influence of buspirone, and its metabolite 1-PP, on the activity of paroxetine in the mouse light/dark paradigm and four plates test. Pharmacology, biochemistry, and behavior. vol 67. issue 1. 2001-01-04. PMID:11113483. |
in the light/dark paradigm, both doses of buspirone significantly potentiated paroxetine, while in the four plates only one dose of buspirone (a 5ht(1a) partial agonist) (0.06 mg/kg) increased the anxiolytic-like effect of paroxetine. |
2001-01-04 |
2023-08-12 |
mouse |
| M Hascoët, M Bourin, B A Nic Dhonnchadh. The influence of buspirone, and its metabolite 1-PP, on the activity of paroxetine in the mouse light/dark paradigm and four plates test. Pharmacology, biochemistry, and behavior. vol 67. issue 1. 2001-01-04. PMID:11113483. |
the results suggested that a balance between pre- and postsynaptic 5-ht(1a) receptor was implicated in the anxiolytic-like effect of paroxetine. |
2001-01-04 |
2023-08-12 |
mouse |
| M Hascoët, M Bourin, B A Nic Dhonnchadh. The influence of buspirone, and its metabolite 1-PP, on the activity of paroxetine in the mouse light/dark paradigm and four plates test. Pharmacology, biochemistry, and behavior. vol 67. issue 1. 2001-01-04. PMID:11113483. |
buspirone seemed to emphasize the role of paroxetine in 5-ht(1a) receptor modulation and exerted a biphasic influence in the two tests. |
2001-01-04 |
2023-08-12 |
mouse |
| I A Pullar, S L Carney, E M Colvin, V L Lucaites, D L Nelson, S Wedle. LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone. European journal of pharmacology. vol 407. issue 1-2. 2000-12-29. PMID:11050288. |
it potentiates potassium-induced [3h]5-ht outflow from prelabelled guinea pig cortical slices both in the presence (ec(50)=950 nm) and absence (ec(50)=250 nm) of a saturating concentration of the 5-ht transport inhibitor, paroxetine, indicating a low level of activity at the 5-ht(1b/1d) autoreceptor. |
2000-12-29 |
2023-08-12 |
rat |
| E Hajós-Korcsok, S F McTavish, T Shar. Effect of a selective 5-hydroxytryptamine reuptake inhibitor on brain extracellular noradrenaline: microdialysis studies using paroxetine. European journal of pharmacology. vol 407. issue 1-2. 2000-12-29. PMID:11050296. |
effect of a selective 5-hydroxytryptamine reuptake inhibitor on brain extracellular noradrenaline: microdialysis studies using paroxetine. |
2000-12-29 |
2023-08-12 |
rat |
| E Hajós-Korcsok, S F McTavish, T Shar. Effect of a selective 5-hydroxytryptamine reuptake inhibitor on brain extracellular noradrenaline: microdialysis studies using paroxetine. European journal of pharmacology. vol 407. issue 1-2. 2000-12-29. PMID:11050296. |
paroxetine (5 mg/kg s.c.) elevated dialysate 5-ht after both acute and repeated (twice daily for 14 days) treatment. |
2000-12-29 |
2023-08-12 |
rat |
| E Hajós-Korcsok, S F McTavish, T Shar. Effect of a selective 5-hydroxytryptamine reuptake inhibitor on brain extracellular noradrenaline: microdialysis studies using paroxetine. European journal of pharmacology. vol 407. issue 1-2. 2000-12-29. PMID:11050296. |
in comparison to paroxetine, desipramine (10 mg/kg s.c.) caused a four-fold increase in dialysate noradrenaline (but did not change 5-ht) following repeated (once daily for 14 days) treatment and a two-fold increase at for acute treatment. |
2000-12-29 |
2023-08-12 |
rat |
| E Hajós-Korcsok, S F McTavish, T Shar. Effect of a selective 5-hydroxytryptamine reuptake inhibitor on brain extracellular noradrenaline: microdialysis studies using paroxetine. European journal of pharmacology. vol 407. issue 1-2. 2000-12-29. PMID:11050296. |
in summary, despite its selectivity as a 5-ht reuptake inhibitor, paroxetine increased extracellular levels of noradrenaline in rat hippocampus following repeated administration. |
2000-12-29 |
2023-08-12 |
rat |